Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer
Molecular Pharmaceutics · 12.11.2026
DOI: 10.1021/acs.molpharmaceut.6c01104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.11.2026. Verfasst von Simranjeet Kaur und 10 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BC Cancer Foundation, University of British Columbia, New Frontiers in Research Fund Transformation Program ?Rare Isotopes to Transform Cancer Therapy?.
Abstract (Originalsprache)
Neurotensin receptor 1 (NTSR1) is overexpressed in many cancers and represents a promising target for PET imaging. Neurotensin (NT)-derived radiopharmaceuticals targeting NTSR1 have been widely investigated; however, their clinical translation is limited in part by rapid proteolytic degradation, particularly at the Arg8−Arg9, Pro10−Tyr11, and Tyr11−Ile12 peptide bonds. In this study, we focused on optimizing the Arg8−Arg9 cleavage site through the incorporation of non-canonical amino acids to improve metabolic stability while maintaining high receptor affinity. A series of 16 DOTA-conjugated NT(6−13) analogs containing modifications at Arg8 and/or Arg9 were synthesized by solid-phase peptide synthesis. The natGa-labeled analogs were evaluated in PC-3 cells using a competition binding assay with [125I-Tyr3]Neurotensin, and compounds with Ki values < 5 nM were selected for 68Ga-radiolabeling, PET imaging, biodistribution, and in vivo stability studies. Ga-SK01033 (Phe(3-guanidine) at Arg8) and Ga-SK02040 (NMe-Orn(Me)3 at Arg8) demonstrated Ki values of 3.35 ± 0.32 and 4.34 ± 1.16 nM, respectively. Both peptides were labeled with 68Ga in 35.0−60.9% decay-corrected radiochemical yields, >108 GBq/μmol molar activity, and >97% radiochemical purity. Despite good binding affinity, [68Ga]Ga-SK01033 exhibited poor in vivo stability and negligible tumor uptake (<1 % ID/g at 1 h p.i., no intact tracer detected at 15 min p.i.). In contrast, [68Ga]Ga-SK02040 displayed improved metabolic stability, with 70.3 ± 5.11% intact tracer at 15 min p.i., resulting in tumor uptake of 11.1 ± 2.64 % ID/g at 1 h p.i. and 9.39 ± 2.64 % ID/g at 3 h p.i. Co-injection of excess natGa-SK02040 reduced tumor uptake by 91.2%, confirming NTSR1-mediated targeting. Overall, these findings demonstrate that while Phe(3-guanidine) substitution improves binding affinity without enhancing stability, incorporation of NMe-Orn(Me)3 at Arg8 simultaneously enhances affinity and metabolic stability, resulting in higher tumor uptake and tumor-to-non-target contrast than previously reported [68Ga]Ga-DOTA-NT-20.3. The present study establishes NMe-Orn(Me)3 as a favorable Arg8 modification that enables the development of NT(6−13)-based PET tracers with improved in vivo performance for targeting NTSR1.
Förderung
- BC Cancer Foundation
- University of British Columbia
- New Frontiers in Research Fund Transformation Program ?Rare Isotopes to Transform Cancer Therapy?
Zitieren
APA
Kaur, S., Yee, K. Y., Pathania, S., Mair, S., Zeisler, J., Cookson, F., Ng, P., Merkens, H., Bénard, F., Lin, K., & Lau, J. (2026). Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c01104
Vancouver
Kaur S, Yee KY, Pathania S, Mair S, Zeisler J, Cookson F, et al. Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c01104
BibTeX
@article{Kaur2026,
author = {Kaur, Simranjeet and Yee, Ka Yee and Pathania, Sheetal and Mair, Stefan and Zeisler, Jutta and Cookson, Finnley and Ng, Pauline and Merkens, Helen and Bénard, François and Lin, Kuo-Shyan and Lau, Joseph},
title = {Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c01104}
}
EUVIMED